King Pharmaceuticals

November 2, 2007

Dear Prescriber:

We would like to inform you that after careful consideration, King Pharmaceuticals®, Inc. has decided to discontinue the manufacture of PROCANBID® (Procainamide Hydrochloride Extended-Release Tablets). This decision is based upon many factors, including our understanding of current medical therapy and the general availability of alternative anti-arrhythmics.

PROCANBID® will remain available through pharmacies and wholesalers until current supplies are depleted. PROCANBID® is distributed through Monarch Pharmaceuticals®, Inc., a wholly owned subsidiary of King Pharmaceuticals®, Inc. No additional product will be available after Monarch, pharmacy, and wholesaler supplies are exhausted.

If you have any questions or concerns, you may contact our Professional Information Services Department at 800-776-3637.

PROCANBID® tablets are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening.

Important Safety Information:

Procanbid® is contraindicated in patients with complete heart block, in patients sensitive to procaine or other ester-type local anesthetics, in those who have an established diagnosis of systemic lupus erythematosus and patients who have been diagnosed with the unusual ventricular arrhythmia called, “les torsades de pointes”. The prolonged administration of procainamide often leads to the development of a positive antinuclear antibody (ANA) test, with or without symptoms of a lupus erythematosus-like syndrome. Procainamide has the potential to produce serious hematologic disorders (0.5%), particularly leukopenia or agranulocytosis (sometimes fatal). Considering the known proarrhythmic properties of procainamide and the lack of evidence of improved survival for any antiarrhythmic drug in patients without life-threatening arrhythmias, the use antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias. Procainamide should be used cautiously in patients with digitalis intoxication, first degree heart block, congestive heart failure, renal insufficiency, myasthenia gravis and in patients receiving concurrent antiarrhythmic medications. Common adverse reactions include dizziness, anorexia, nausea, vomiting, abdominal pain, bitter taste and diarrhea.

Sincerely,

Eric Carter, PhD, MD
Chief Science Officer

Please see accompanying full Prescribing Information.